Structure’s oral GLP-1 a ‘work in progress’ following Phase IIa obesity and diabetes data

Phase IIa data for Structure Therapeutics’ oral GLP-1 drug candidate for type 2 diabetes and obesity bested analyst expectations on safety and tolerability, but lower-than-hoped-for efficacy results set it up for more work in the next round of testing in 2024.

The San Francisco biotech’s once-daily oral candidate, GSBR-1290, is being…
Click here to view original post